# [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib

> **NCT02175095** · NA · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 68 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Regorafenib
- **DIAGNOSTIC_TEST:** [18F]FLT-PET
- **DIAGNOSTIC_TEST:** [18F]FDG-PET

## Key facts

- **NCT ID:** NCT02175095
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-18
- **Primary completion:** 2016-08-10
- **Final completion:** 2019-04-30
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2024-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02175095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02175095, "[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02175095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*